Skip to main content
OpenTrials
Completed

NCT Number: NCT06316128

EmploYEd Antithrombotic Therapies in Patients With Acute Coronary Syndromes HOspitalized in iTalian CCUs

This registry has the aim to assess the use of different antithrombotic therapies, including untested drug combinations, routinely used during the hospitalization phase, with their timing, route and dose of administration, in consecutive patients discharged with a diagnosis NSTEMI or STEMI in Italian Cardiac care Units (CCUs) during a four-week study period.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ospedale Santo Spirito - Sc Cardiologia, Casale, AL, Italy

Loading trial locations.

About this study

EYESHOT-2 is a prospective, multicenter, observational, nationwide survey of patients discharged with a diagnosis NSTEMI or STEMI admitted to Italian CCUs.

The survey will be designed to include all consecutive patients, who met the eligibility criteria, admitted in hospitals with or without cardiac catheterization laboratories and cardiac surgery facilities during a period of 4 weeks.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All consecutive patients aged 18 years or more, discharged with diagnosis of myocardial infarction (NSTEMI or STEMI) admitted to CCUs undergoing myocardial revascularization (PCI or CABG) or conservative treatment. At presentation, the diagnosis of NSTEMI will be based on the measurement of troponins and assessment of ECG changes, as suggested by European Society of Cardiology (ESC) guidelines; the diagnosis of STEMI will be characterized by an acute chest pain and persistent (>20 min) ST-segment elevation ≥ 1mm in two or more limb leads, or contiguous pre-cordial leads or left bundle branch block.
  • Written informed consent signed. Patients who cannot provide the informed consent due to very severe clinical conditions can give their consent some hours/days after admission, when more favourable clinical conditions allow them to receive the appropriate information. Patients having died before giving informed consent may also be included unless the local Institutional Review Board (IRB) does not allow this procedure. In that case, it is strongly suggested to obtain relative(s) agreement through the collect of a signed informed consent.

Exclusion criteria

  • Patients with a diagnosis of Unstable Angina,
  • Patients developing MI after PCI or CABG,
  • MI following non-cardiac surgery or traumatic causes,
  • Patients with chest pain without elevation of troponin,
  • Patients enrolled in Randomized Controlled Trial (RCTs),
  • Patients already enrolled into the study from another CCU

Treatment and study plan

Primary outcomes

  1. Antithrombotic therapies

    Time frame: 1 week

    The primary objective of the study is to describe at a national level the different antithrombotic therapies (alone or in combination) commonly employed from admission to discharge in NSTEMI or STEMI patients undergoing different therapeutic strategies (PCI, CABG, conservative). A particular focus will be given to antithrombotic therapies (combinations, timing of administration, indications) used (a) before PCI (pre-treatment) (b) in the cath lab during PCI [use of Glycoprotein IIb/IIIa inhibitors (GPIs), cangrelor, anticoagulants] and (c) during hospital stay.

Other outcomes

  1. Assessment of in-hospital clinical events

    Time frame: 1 week

    An exploratory objective is the assessment of the rate of in-hospital clinical events (ischemic and hemorrhagic) in a large setting of NSTEMI or STEMI patients admitted to CCUs treated with different revascularization strategies and combinations of antithrombotic agents.

Sponsors and collaborators

Lead sponsor

Heart Care Foundation

Other

Registry information

Acronym: EYESHOT-2

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Mar 18, 2024
Registry last updated
Jan 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.